2015 Fiscal Year Final Research Report
Development of a novel vaccine therapy using nanoparticles and cross-presentation machinery
| Project/Area Number |
25461186
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
Suda Takafumi 浜松医科大学, 医学部, 教授 (30291397)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 気管支喘息 / ワクチン療法 / ナノ粒子 / 樹状細胞 / 細胞障害性T細胞 |
|---|
| Outline of Final Research Achievements |
In this study, nanoparticle, which consists of polylactic coglycolic acid (PLGA), was used to induce allergen specific cytotoxic T-lymphocytes (CTL). PLGA facilitates the induction of CTL via cross-presentation machinery in antigen-presenting cells (APC), and these CTL can kill dendritic cell (DC) that plays a role in bronchial asthma.
We found PLGA efficiently induced ovalbumin (OVA)-specific CTL via antigen-presenting cells in vitro. Next, PLGA/OVA was intranasally administered to OVA-induced asthma model mice. PLGA/OVA reduced eosinophil number in bronchoalveolar lavage compared to that after treatment with OVA alone. However, PLGA/OVA could not significantly reduce eosinophil number or induce allergen-specific CTL compared to those of untreated mice. There is a possibility that more manipulation of PLGA/OVA is necessary to improve the delivery and phagocytosis of allergen in APC and to facilitate cross-presentation in vivo.
|
| Free Research Field |
細胞性免疫学
|
